Ignite Creation Date:
2024-05-05 @ 7:11 PM
Last Modification Date:
2024-10-26 @ 9:45 AM
Study NCT ID:
NCT00622609
Status:
COMPLETED
Last Update Posted:
2017-07-21
First Post:
2008-02-13
Brief Title:
Anti-MAG First Administration to Human
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Single-blind Single Dose Placebo Controlled First Time in Human Study to Assess the Safety Tolerability and Pharmacokinetics of Ascending Doses of GSK249320 in Healthy Volunteers
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
GSK249320 is a monoclonal antibody directed against myelin associated glycoprotein MAG a protein that inhibits axonal regeneration GSK249320 acts as a MAG antagonist and through this activity it is hypothesised that it will enhance recovery from neuronal degeneration following acute axonal injury which occurs in spinal cord injury or stroke
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None